ɬÀï·¬

Journal News

JBC: Serpins in wasp venom block host immune response

Mariana Figuera-Losada
By Mariana Figuera-Losada
May 1, 2017

In May 1860, a bewildered Charles Darwin wrote a letter to the botanist Asa Gray to say, “I cannot persuade myself that a beneficent and omnipotent God would have designedly created the Ichneumonidae with the express intention of their feeding within the living bodies of caterpillars.”

Darwin was referring to parasitoid wasps. This group of insects is estimated to have up to 600,000 species, according to at the Institute of Insect Science in Zhejiang University in China. The number makes parasitoid wasps the most abundant and diverse group of insects on Earth. The study of some of the molecular mechanisms of the relationship between one of these parasitoid wasps and its host, a butterfly, is the subject of Ye’s in the . Ye and colleagues described the discovery of a splicing isoform of a serine protease inhibitor found in the venom of the wasp that can inhibit its host’s immunity.

Endoparasitoid wasps lay their eggs inside the body of their hosts, while ectoparasitoid wasps do so on the body surface of their hosts. Eggs hatch and feed on the hosts, killing them.

P. puparum lays its eggs in a butterfly pupa
Courtesy of Gongyin Ye
P. puparum lays its eggs in a butterfly pupa.

Most of the known pest insects that attack crops are preyed upon by parasitoid wasps, which is why they regularly have been deployed to protect crops. Pteromalus puparum is a gregarious endoparasitoid wasp that attacks the pupal stage of several butterfly species, including Pieris rapae, the cabbage white butterfly, which can be a problem in commercial farming of cabbage, broccoli and cauliflower.

Ye explains that to increase the chance of survival of its offspring, these wasps inject venom along with their eggs to suppress host immune defenses. Melanization, one of the processes of host immunity, is a conserved and highly regulated process. It consists of a series of serine protease activation reactions that culminate in the production of prophenoloxidase-activating proteases, which further catalyze the conversion of prophenoloxidase into phenoloxidase. In turn, phenoloxidase oxidizes tyrosine and o-diphenols to quinones, which polymerize to form melanin that can cover the surface of pest invaders and keep them from spreading or hatching and completing development.

In a previous study, using a combination of transcriptomic and proteomic approaches, Ye and colleagues found that the venom of P. puparum contains at least 70 different putative proteins that include proteases, inhibitors, and recognition and binding proteins.

In the JBC paper, Ye and colleagues show that the P. puparum venom blocks melanization by both the host pupae and larvae. By using a number of protein fractionation steps followed by sequence analyses of the isolated proteins, the authors identified a serine protease inhibitor or serpin. They named this inhibitor PpS1V.

Serpins are a family of inhibitors that react with their target protease via a reactive center loop to form an inactive complex. Ye and colleagues found that PpS1V is one of the 16 predicted putative splicing isoforms that differ in their eighth and last exon, which contains the reactive center loop. They found that PpS1V binds and inhibits the activity of a previously unknown host protein, which they called P. rapae prophenoloxidase-activating proteinase 1, which is possibly involved in melanization by the host.

Ye thinks that uncovering the mechanisms by which parasitoid wasps inhibit host immunity will yield potential candidates for novel insecticides. Considering the parasitoid wasps’ diversity, these animals are an untapped source of bioactive compounds for pest control and drug discovery.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Mariana Figuera-Losada
Mariana Figuera-Losada

Mariana Figuera-Losada is a research consultant at Montefiore Medical Center.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent ɬÀï·¬ paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent ɬÀï·¬ paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.